Search clinical trials for: glatiramer acetate

Total 3448 results

Biogen

Recruiting

A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Multiple Sclerosis

United States
Novartis Pharmaceuticals

Recruiting

A NIS Evaluating Injectable Treatments in Patients With Relapsing Multiple Sclerosis (AIOLOS)

Relapsing Multiple Sclerosis

Germany
Novartis Pharmaceuticals

Recruiting

Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS (STHENOS)

Multiple Sclerosis

Germany, Spain, Italy, France, United Kingdom
Amsterdam UMC, location VUmc

Recruiting

Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS). (DOT-MS)

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis, Secondary Progressive

Netherlands
Johns Hopkins University
Patient-Centered Outcomes Research Institute; National Multiple Sclerosis Society

Recruiting

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (TREAT-MS)

Multiple Sclerosis, Relapsing-Remitting

United States
The Cleveland Clinic
University of Nottingham

Active, not recruiting

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (DELIVER-MS)

Multiple Sclerosis, Relapsing-Remitting

United States, United Kingdom
Takeda

Completed

Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"

Multiple Sclerosis

Japan
Novartis Pharmaceuticals

Completed

A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Relapsing Multiple Sclerosis (RMS)

United States
Pfizer

Completed

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

Crohn's Disease

United States, Spain, Lebanon, Australia, Russian Federation, Korea, Republic of, Tunisia, Italy, Poland, Belgium, Austria, Germany, Saudi Arabia, Czechia, Hungary, Switzerland, Turkey, Slovakia, Ukraine, Georgia, Bosnia and Herzegovina and more
Mapi Pharma Ltd.

Active, not recruiting

Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS

Multiple Sclerosis

Israel
Genzyme, a Sanofi Company

Active, not recruiting

A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT (LemKids)

Multiple Sclerosis

Portugal, Turkey, Italy, Austria, Belgium, France, Netherlands, Poland, Russian Federation, United Kingdom
University of Nebraska
Teva Branded Pharmaceutical Products R&D, Inc.

Withdrawn

The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections

Multiple Sclerosis

United States
Hadassah Medical Organization
Weizmann Institute of Science

Completed

Asses the Anti-inflammatory Effects of Short Term Copaxone Therapy on Patients the Acute Decompensated Heart Failure (Copaxone)

Heart Failure | Inflammatory Response | Acute Decompensated Heart Failure | Cytokine Storm

Israel
Al-Azhar University
Benha University

Completed

Direct Versus US Guided PECS Block on Controlling Postmastectomy Pain

Postmastectomy Pain

Egypt
Transgene

Terminated

Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.

Colorectal Neoplasm | Digestive System Neoplasm

France, Spain, Belgium
Transgene

Terminated

Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer

Colorectal Neoplasms

France, United Kingdom
Biogen

Withdrawn

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)

Relapsing Multiple Sclerosis
University of Kansas Medical Center

Active, not recruiting

A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors

Basal Cell Carcinoma | Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
IMPULS Endowment Fund

Completed

Czech Pharmaco-epidemiological Study on Disease Modifying Drugs (CPE)

Multiple Sclerosis

Czechia
Karolinska Institutet
Patient-Centered Outcomes Research Institute; Kaiser Foundation Research Institute

Active, not recruiting

COMparison Between All immunoTherapies for Multiple Sclerosis. (COMBAT-MS)

Relapsing-remitting Multiple Sclerosis

Sweden
Teva Pharmaceutical Industries, Ltd.

Completed

Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Belgium, France, Germany, Israel, Italy, United Kingdom
National Cancer Institute, Egypt

Completed

Erector Spinae Plane Block for Post-thoracotomy Pain Control

Post-thoracotomy Pain Syndrome

Egypt
OSF Healthcare System

Completed

Correlation Between Relapses in Multiple Sclerosis (MS) and Vitamin D Intake

Multiple Sclerosis

United States
University of Colorado, Denver

Completed

Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate

Multiple Sclerosis

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo (GALA)

Relapsing Remitting Multiple Sclerosis

United States, Bulgaria, Croatia, Czechia, Estonia, Georgia, Germany, Hungary, Israel, Italy, Lithuania, Poland, Romania, Russian Federation, South Africa, Ukraine, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone® (CONFIDENCE)

Multiple Sclerosis

United States, Argentina, Austria, Belgium, Croatia, Finland, France, Germany, Ireland, Italy, Mexico, Poland, Puerto Rico, Russian Federation, Spain, Turkey
University of Medicine and Dentistry of New Jersey

Completed

Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI (BECOME)

Multiple Sclerosis

United States
Biocad

Completed

Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis
Cinnagen

Completed

Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran

Relapsing Multiple Sclerosis
University at Buffalo
Teva Neuroscience, Inc.

Completed

Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)

Multiple Sclerosis

United States
Spectrum Pharmaceuticals, Inc

Completed

Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment

Non-small Cell Lung Cancer

United States, Czechia, India, Brazil, Argentina, Hungary
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness

Relapsing-Remitting Multiple Sclerosis

United States
Novartis Pharmaceuticals

Terminated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone (ASSESS)

Relapsing-remitting Multiple Sclerosis (RRMS)

United States, Canada, Mexico, Brazil, Puerto Rico, Argentina, Chile
Isfahan University of Medical Sciences

Completed

Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients

Secondary Progressive Multiple Sclerosis

Iran, Islamic Republic of
Montefiore Medical Center
Rett Syndrome Research Trust

Completed

Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)

Rett Syndrome

United States
Johns Hopkins University

Withdrawn

High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis (HiCy)

Relapsing Remitting Multiple Sclerosis

United States
EMD Serono
Pfizer

Completed

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

United States, United Kingdom, Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russian Federation, Spain, Switzerland
University of Colorado, Denver
Rocky Mountain MS Research Group, LLC

Completed

Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate (GATEWAYII)

Multiple Sclerosis

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)

Optic Neuritis
Biogen

Completed

Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS) (EFFECT)

Multiple Sclerosis

United States, Italy, Hungary, United Kingdom, Spain, France, Australia, Germany, Canada, Switzerland, Argentina, Czech Republic, Croatia
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety of New Formulation of Glatiramer Acetate (Song)

Relapsing Remitting Multiple Sclerosis
Teva Neuroscience, Inc.

Completed

A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®

Multiple Sclerosis

United States
Synthon BV

Completed

Efficacy and Safety of GTR in Comparison to Copaxone® (GATE)

Multiple Sclerosis

United States, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Georgia, Germany, Italy, Mexico, Moldova, Republic of, Poland, Romania, Russian Federation, Serbia, South Africa, Ukraine, United Kingdom
University at Buffalo
Teva Pharmaceuticals USA

Completed

Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis

Multiple Sclerosis

United States
National Institute of Allergy and Infectious Diseases...
Autoimmunity Centers of Excellence

Completed

Treatment of Multiple Sclerosis With Copaxone and Albuterol

Multiple Sclerosis | Autoimmune Diseases

United States
University of California, Los Angeles
Johns Hopkins University; University of Colorado, Denver; Mayo Clinic; University... and other collaborators

Completed

A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS) (Estriol-MS)

Relapsing Remitting Multiple Sclerosis

United States, Canada
EMD Serono

Terminated

Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)

Relapsing Remitting Multiple Sclerosis

United States, Croatia, Bulgaria, Czech Republic, Italy, Mexico, Russian Federation, South Africa, Spain, Turkey, Hungary, Poland, Ukraine, Finland, United Kingdom, Greece, Serbia
Rutgers, The State University of New Jersey

Completed

Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells

Multiple Sclerosis

United States
Biogen

Terminated

Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve) (IMPROVE)

Multiple Sclerosis, Relapsing-Remitting | Relapsing-Remitting Multiple Sclerosis

Canada
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety and Tolerability of Glatiramer Acetate (GLACIER)

Relapsing-Remitting Multiple Sclerosis

United States

Search clinical trials for: glatiramer acetate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations